May 14, 2021
EA Pharma Co., Ltd.

EA Pharma Presents Data about Orally Available α4β7 Integrin Antagonist
AJM347 in DDW2021
EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Chuo-ku, Tokyo, Japan; “EAPharma”) will give ePoster presentations of data about EA Pharma’s originated anddeveloped inflammatory bowel disease treatment (Development Code AJM347) in Digestive
Disease Week (DDW), May 21-23, 2021, Virtual Event.
AJM347 is an orally available and small molecular selective antagonist of α4β7 integrin. In
inflammatory bowel disease（IBD）, lymphocytes and other inflammatory cells excessively
coagulate and invade into the inflamed site. The series of reactions are mediated by bindingof integrins expressed on the surface of inflammatory cells to adhesion molecules (MAdCAM1, etc.) excessively expressed on endothelial cells in the intestinal mucosa. AJM347 canselectively antagonize α4β7 integrin to inhibit cell adhesion mediated by binding to MAdCAM1, which suppresses invasion of lymphocytes into the inflamed site to exert anti-inflammation
effects.
In DDW 2021, EA Pharma is scheduled to present AJM347 PI clinical study data (AbstractNo. Fr535) and preclinical pharmacological data (Abstract No. Fr480).
＜Study Data to be presented＞
AbstractTitle

No.

Date and time ofe-presentation(Eastern Daylight Time(UTC-4))

Fr535

ORAL ALPHA 4 BETA 7 INTEGRIN ANTAGONIST

Friday, May 21

AJM347 DEMONSTRATES SUSTAINED TARGET

ePoster presentation

ENGAGEMENT IN A FIRST-IN-HUMAN STUDY IN
HEALTHY VOLUNTEERS：
AJM347 PI Clinical study results
Fr480

PHARMACOLOGICAL CHARACTERIZATION OF

Friday, May 21

AJM347: A NOVEL, ORALLY ACTIVE AND SMALL

ePoster presentation

MOLECULAR PRODRUG OF ALPHA 4 BETA 7SELECTIVE INTEGRIN ANTAGONIST FOR
INFLAMMATORY BOWEL DISEASE：
AJM347 Preclinical pharmacological study resultsAs a gastrointestinal specialty pharma, EA Pharma strives to create innovative
pharmaceuticals to increase treatment options for patients with IBD, aiming to contribute toQOL(quality of life) of patients and their families

Media Inquiries
EA Pharma Co., Ltd.
Corporate Planning Dept.
TEL： +81(0)3-6280-9802
More Information
1. About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, wasestablished in April 2016 by integration of the gastrointestinal business unit with more than
60 year’s history of the Eisai Group and the gastrointestinal business unit of the AjinomotoGroup having amino acid as its business core. EA Pharma Co., Ltd., is a gastrointestinal
specialty pharmaceutical company with a full value chain covering R&D, production &logistics and sales & marketing.
For further information on EA Pharma Co., Ltd., please visit
http://www.eapharma.co.jp/en/
2. About inflammatory bowel disease (IBD)
Inflammatory bowel disease is a group of diseases that include ulcerative colitis (UC) andCrohn’s disease (CD). In these diseases, ulcers are formed in the intestinal mucosa. The
major symptoms of IBD include abdominal pain, diarrhea and bloody stools. In many cases,
the “remission” stage where the symptoms improve and the “relapse” stage where thesymptoms deteriorate repeat over time, and patients suffer from the decline of QOL. The
mechanism of onset is unknown up to the present. In Japan, IBD is one of the “designatedintractable disease” by Ministry of Health, Labour and Welfare. The registered patient number
amounts to about 220,000 of UC and about 70,000 of CD in Japan. The number of patients
suffering from IBD has a tendency to increase in recent years.1)

Source1) “Basic treatment guidance for patients with ulcerative colitis” (revised March 2020), “Basic treatment guidance forpatients with Crohn’s disease” (revised March 2020), both edited by Research group for intractable inflammatory bowel
diseases, Research project on rare and intractable diseases, Health and Labour Sciences Research Grants.